Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRVS
stocks logo

CRVS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.129
-28.09%
--
--
-0.137
-167.63%
--
--
-0.134
+33.5%
Estimates Revision
The market is revising No Change the revenue expectations for Corvus Pharmaceuticals, Inc. (CRVS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 43.02%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.76%
In Past 3 Month
Stock Price
Go Up
up Image
+43.02%
In Past 3 Month
Wall Street analysts forecast CRVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVS is 13.33 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CRVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVS is 13.33 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.810
sliders
Low
11.00
Averages
13.33
High
16.00
Current: 8.810
sliders
Low
11.00
Averages
13.33
High
16.00
Mizuho
Outperform
maintain
$11 -> $13
2025-10-29
Reason
Mizuho
Price Target
$11 -> $13
2025-10-29
maintain
Outperform
Reason
Mizuho raised the firm's price target on Corvus Pharmaceuticals to $13 from $11 and keeps an Outperform rating on the shares.
Oppenheimer
Jeff Jones
Outperform
to
Outperform
downgrade
$17 -> $15
2025-08-08
Reason
Oppenheimer
Jeff Jones
Price Target
$17 -> $15
2025-08-08
downgrade
Outperform
to
Outperform
Reason
Oppenheimer analyst Jeff Jones lowered the firm's price target on Corvus Pharmaceuticals to $15 from $17 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 results and provided an update on plans for soquelitnib across multiple indications. Oppenheimer models a $100M financing in 2026 to extend runway with model refinements.
Mizuho
Graig Suvannavejh
Outperform
to
Outperform
downgrade
$12 -> $11
2025-05-20
Reason
Mizuho
Graig Suvannavejh
Price Target
$12 -> $11
2025-05-20
downgrade
Outperform
to
Outperform
Reason
Oppenheimer
Oppenheimer
Outperform
maintain
$15 -> $17
2025-05-09
Reason
Oppenheimer
Oppenheimer
Price Target
$15 -> $17
2025-05-09
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Corvus Pharmaceuticals to $17 from $15 and keeps an Outperform rating on the shares. The firm notes that on Thursday afternoon, the company provided a Q1 business update alongside an in-depth review of their Phase 1 data for soquelitnib in AD, ahead of presentations at SID during the coming days. The AD update continues to support Oppenheimer's enthusiasm for the candidate in this potential blockbuster indication with EASI 75 responses achieved in 63% of Cohort 3 patients, while consistently seeing earlier, deeper, and non-plateauing responses through 28 days of dosing. The firm views these data as highly competitive with dupilimab and other systemic options for patients with AD.
HC Wainwright & Co.
Sean Lee
Strong Buy
Reiterates
$11
2025-03-26
Reason
HC Wainwright & Co.
Sean Lee
Price Target
$11
2025-03-26
Reiterates
Strong Buy
Reason
Oppenheimer
Jeff Jones
Buy
Maintains
$14 → $15
2025-03-26
Reason
Oppenheimer
Jeff Jones
Price Target
$14 → $15
2025-03-26
Maintains
Buy
Reason
Oppenheimer raised the firm's price target on Corvus Pharmaceuticals to $15 from $14 and keeps an Outperform rating on the shares after the company released year-end results and provided a business update. Clinical studies for soquelitinib are on track with updated Phase 1 data in AD anticipated at the Society for Investigative Dermatology in May. An update was just presented at the T Cell Lymphoma Forum last week, which provided longer-term follow for patients in the Phase 1b study, the firm says. Oppenheimer believes year-end cash of $52M remains a concern, with this amount insufficient to complete the ongoing Phase 3 study.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Corvus Pharmaceuticals Inc (CRVS.O) is -15.85, compared to its 5-year average forward P/E of -5.06. For a more detailed relative valuation and DCF analysis to assess Corvus Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.06
Current PE
-15.85
Overvalued PE
-0.96
Undervalued PE
-9.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.61
Undervalued EV/EBITDA
-3.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
50.94
Current PS
0.00
Overvalued PS
209.32
Undervalued PS
-107.44
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CRVS News & Events

Events Timeline

(ET)
2025-11-04
17:36:52
Corvus Pharmaceuticals announces Q3 EPS of 12 cents, matching consensus expectations.
select
2025-08-07 (ET)
2025-08-07
16:22:34
Corvus Pharmaceuticals reports Q2 EPS (10c), consensus (12c)
select
2025-06-25 (ET)
2025-06-25
08:02:30
Corvus announces IND application approved by CDE of China NMPA to start trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
10-21Newsfilter
IFLI Names Dr. Mehrdad Mobasher and Dr. Carol O'Hear as Executive Partners to Drive Innovation in Follicular Lymphoma

  • New Appointments at IFLI: The Institute for Follicular Lymphoma Innovation (IFLI) has appointed Dr. Mehrdad Mobasher and Dr. Carol O'Hear as Executive Partners, bringing extensive experience in drug development and strategic leadership to the organization.

  • Dr. Mobasher's Background: Dr. Mobasher has over 20 years of experience in hematology/oncology, previously serving as Chief Medical Officer at BeOne and holding significant roles at Zai Lab and Genentech, where he contributed to the development of key oncology therapies.

  • Dr. O'Hear's Expertise: Dr. O'Hear, with a strong background in drug discovery and clinical development, has held leadership positions at Exelixis and Gilead, focusing on expanding clinical programs for innovative cancer treatments.

  • IFLI's Mission: IFLI is dedicated to accelerating innovative treatment options for follicular lymphoma patients through research, technology, and collaboration, aiming to develop novel therapeutics and biomarkers while promoting knowledge exchange among researchers.

[object Object]
Preview
9.0
10-17Newsfilter
Corvus Pharmaceuticals to Present Interim Findings from Phase 1b/2 Trial of Ciforadenant for Metastatic Renal Cell Cancer at ESMO Congress 2025

  • Clinical Trial Overview: A Phase 1b/2 clinical trial is assessing ciforadenant as a first-line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab and nivolumab, with interim data presented at the ESMO Congress 2025 indicating the triplet therapy is feasible and well tolerated.

  • Interim Results: The trial showed a deep response rate of 34% and an overall response rate of 46%, with a median progression-free survival of 11.04 months, suggesting potential benefits of blocking adenosine signaling in RCC patients despite the challenging disease characteristics of the enrolled participants.

[object Object]
Preview
9.5
08-08Yahoo Finance
Corvus: Q2 Earnings Snapshot

  • Financial Performance: Corvus Pharmaceuticals Inc. reported a loss of $8 million in the second quarter, translating to a loss of 10 cents per share.

  • Market Expectations: The company's results exceeded Wall Street expectations, which had estimated a loss of 13 cents per share according to analysts from Zacks Investment Research.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Corvus Pharmaceuticals Inc (CRVS) stock price today?

The current price of CRVS is 8.81 USD — it has increased 4.38 % in the last trading day.

arrow icon

What is Corvus Pharmaceuticals Inc (CRVS)'s business?

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

arrow icon

What is the price predicton of CRVS Stock?

Wall Street analysts forecast CRVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVS is 13.33 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Corvus Pharmaceuticals Inc (CRVS)'s revenue for the last quarter?

Corvus Pharmaceuticals Inc revenue for the last quarter amounts to -10.57M USD, increased 45.72 % YoY.

arrow icon

What is Corvus Pharmaceuticals Inc (CRVS)'s earnings per share (EPS) for the last quarter?

Corvus Pharmaceuticals Inc. EPS for the last quarter amounts to -9566000.00 USD, increased 51.34 % YoY.

arrow icon

What changes have occurred in the market's expectations for Corvus Pharmaceuticals Inc (CRVS)'s fundamentals?

The market is revising No Change the revenue expectations for Corvus Pharmaceuticals, Inc. (CRVS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 43.02%.
arrow icon

How many employees does Corvus Pharmaceuticals Inc (CRVS). have?

Corvus Pharmaceuticals Inc (CRVS) has 31 emplpoyees as of December 05 2025.

arrow icon

What is Corvus Pharmaceuticals Inc (CRVS) market cap?

Today CRVS has the market capitalization of 657.95M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free